ESTRACOMB 10 MG
ESTRADIOL : 10 MG NORETHINDRONE ACETATE : 30 MG ESTRADIOL : 4 MG · DIN 02108186 · NOVARTIS PHARMACEUTICALS CANADA INC
Health Canada status: CANCELLED POST MARKET
What is ESTRACOMB?
ESTRACOMB 10 MG contains ESTRADIOL : 10 MG NORETHINDRONE ACETATE : 30 MG ESTRADIOL : 4 MG. It is listed in the Health Canada Drug Product Database under DIN 02108186, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as PATCH for TRANSDERMAL administration. Health Canada currently lists it as cancelled post market, status dated 08-Jun-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ESTRACOMB used for?
Relief of menopausal symptoms and prevention of osteoporosis in women with intact uteri. Use only when benefits outweigh risks.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02108186 |
|---|---|
| Brand name | ESTRACOMB |
| Generic / active ingredient | ESTRADIOL : 10 MG NORETHINDRONE ACETATE : 30 MG ESTRADIOL : 4 MG |
| Manufacturer | NOVARTIS PHARMACEUTICALS CANADA INC |
| Strength | 10 MG |
| Dosage form | PATCH |
| Route of administration | TRANSDERMAL |
| Schedule | Prescription |
| ATC code | G03FB05 NORETHISTERONE AND ESTROGEN |
| AHFS class | 68:16.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 08-Jun-2009 |
| Original market date | 1994-12-31 00:00:00 |
How is it administered?
Transdermal patches. ESTRADERM 50 applied twice weekly for first 2 weeks, followed by ESTRAGEST 250/50 applied twice weekly for next 2 weeks of a 4-week cycle. Use lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text (Table of Contents lists page 27, but text ends before that).
How is it supplied?
Patches of ESTRADERM 50 µg and Patches of ESTRAGEST 250/50 µg. (Specific pack sizes like 'bottles of 100' not in text).
Contraindications
Liver disease, estrogen/progestin-dependent cancer, endometrial hyperplasia, breast cancer, undiagnosed bleeding, pregnancy, thromboembolic disease, thrombophilic disorders, migraine, breastfeeding.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Not for cardiovascular disease prevention. Use shortest duration possible. Risk of dementia in women >65.
What can be used instead?
Other Canadian products sharing ATC code G03FB05 NORETHISTERONE AND ESTROGEN. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ESTALIS SEQUI | 0.62 MG | PATCH | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02243529 |
| ESTALIS SEQUI | 4.8 MG | PATCH | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02243530 |
Who else supplies NORETHISTERONE AND ESTROGEN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NORETHISTERONE AND ESTROGEN appears in 14 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.